Affection Animal Pharmaceuticals Secures C+ Round Financing to Lead Innovation in Pet Vaccines

VCBeat has learned that recently,Suzhou Aiyi Animal Medicine Co., Ltd.(Affection Animal Pharmaceuticals, abbreviated as “Aiyi Animal Medicine”) has successfully completed a C+ round of financing worth hundreds of millions of RMB. This equity financing round was led byFosun Health CapitalLead investor,Suzhou Venture Capital · Guofa Venture CapitalandTaiwanese Businessmen Development Investment FundCo-investment.

Suzhou Aiyi Animal Medicine Co., Ltd. is a leading Chinese pet vaccine company dedicated to the R&D, registration, and production of internationally top-tier pet vaccines, addressing the long-standing issues of limited product variety and strain mismatch in China’s pet vaccine market. Its product pipeline includes key pet vaccine varieties currently lacking in China, globally innovative vaccines targeting both Chinese and international markets, as well as domestically produced alternatives and upgraded versions of existing imported pet vaccines.

Dr. Zhu Xianzhu, Founder and President of the Company,He has served as Executive Vice President, Vice President, Chief Biological Products Officer, and Head of Global R&D at multinational corporations such as Fort Dodge Animal Health, Pfizer Animal Health (now Zoetis), Elanco Animal Health, and Ceva Santé Animale. The Aiyi Animal Medicine team he built and led has cumulatively developed and registered over one hundred animal vaccines and pharmaceuticals, making it the team with the most extensive R&D experience and the most outstanding achievements in the global pet vaccine sector. To date, Suzhou Aiyi Animal Medicine Co., Ltd. has completed six rounds of financing, securing investment and support from multiple USD- and RMB-denominated private equity funds, industrial capital, and local government guidance funds.

The product with the most advanced R&D and registration progress at Suzhou Aiyi Animal Medicine Co., Ltd. is the Canine Bordetella bronchiseptica Vaccine (Mucosal Immunity)., also commonly known as the kennel cough vaccine or Bb vaccine, is an important canine vaccine internationally. It is used to prevent respiratory diseases such as coughing and wheezing caused by Bordetella bronchiseptica infection in dogs, as well as to reduce the risk of severe illness and death. Canine Bordetella bronchiseptica (Bordetella bronchiseptica, B.b.), a Gram-negative bacillus belonging to the genus Bordetella, is one of the primary pathogens responsible for canine infectious respiratory disease (CIRD), commonly known as kennel cough. Bordetella bronchiseptica not only causes upper respiratory tract infections in dogs but also increases the risk of secondary respiratory infections and co-infections. This pathogen poses significant health and life threats to pet dogs, causing concern and impact for pet-owning households.

Furthermore, Suzhou Aiyi Animal Medicine Co., Ltd. is developing globally innovative pet vaccine products, such as sexual characteristic control vaccines for pets (also known as “contraceptive vaccines”).Aiyi’s canine sexual characteristic control vaccine is administered via subcutaneous injection, offering the advantages of being humane and non-invasive. This animal-friendly approach eliminates the surgical and anesthesia concerns often raised by pet owners. Trial data for the vaccine demonstrate favorable safety and efficacy profiles; it effectively elevates serum anti-GnRH antibody levels and suppresses sex hormone secretion, thereby controlling sexual characteristics and improving undesirable behaviors in dogs.

Meanwhile, this product can avoid the issues of skeletal development and later-onset obesity caused by castration surgery. Its impact on canine reproductive capacity is reversible, offering a new solution for pet behavior improvement beyond castration surgery. This product is the world’s first dog sexual characteristic control vaccine to enter the clinical stage.

Representatives of the investors in this round,Xu Bei, Managing Director of Fosun Health Capital“He stated: ‘China’s pet healthcare consumption industry is in a phase of vigorous growth, presenting significant market opportunities for high-end veterinary biological products such as pet vaccines. The management team of Suzhou Aiyi Animal Medicine Co., Ltd., led by its founder Dr. Zhu Xianzhu, boasts extensive experience and remarkable achievements in the global R&D of pet vaccines. Aiyi’s product R&D capabilities and pipeline layout have been fully recognized by Fosun Health Capital and Fosun Pharma. We believe that Aiyi will grow into a leading enterprise in China’s pet vaccine industry. Through this investment, Fosun Health Capital will not only provide long-term financial support to Aiyi Animal Medicine but also leverage Fosun Pharma’s extensive industrial ecosystem resources to help Aiyi achieve its R&D and commercialization goals, accelerate the clinical application of innovative pet vaccines, and serve as a solid partner for the company.’”

Fosun Health Capital (Shanghai Fosun Health Equity Investment Fund Management Co., Ltd.) is a core industrial investment platform initiated and established by Fosun Pharma. Leveraging Fosun Pharma’s over three decades of industry accumulation and its experience collaborating with top-tier domestic and international funds and companies, the firm focuses on investments in the healthcare and wellness sector. It manages 11 RMB-denominated funds with assets under management exceeding RMB 10 billion, covering all investment stages from start-up to maturity across multiple fields, including pharmaceuticals, medical devices, and diagnostics. Through its unique “investment + industry” dual-drive model, combined with scientific research and operational support, Fosun Health Capital provides full-cycle empowerment to its portfolio companies, facilitating horizontal industrial expansion and vertical ecosystem building. Adhering to the principles of value investing, Fosun Health Capital is committed to becoming a discoverer, connector, and long-term strategic partner for high-quality enterprises in the global healthcare sector.

Suzhou International Development Venture Capital Holding Co., Ltd. (“Guofa VC”) has a registered capital of RMB 3.8 billion. As a professional equity investment institution under the Suzhou Venture Capital Group, it gives full play to the “guiding, demonstrative, and amplifying” role of state-owned capital. Adhering to financial capital as the link and market economy as the orientation, it leverages its resource integration capabilities to build four major business segments: government guidance funds, equity investment, asset management, and debt financing, with assets under management nearing RMB 130 billion. Focusing on Suzhou’s four pillar industries, Guofa VC prioritizes strategic emerging sectors such as advanced equipment manufacturing, new materials, next-generation information technology, energy conservation and environmental protection, life and health (including biotechnology), and modern services. It has helped more than 70 companies achieve listings or quotations on domestic and international capital markets.

The Kunshan Taiwan Business Development Investment Fund is a collaborative fund established by CDIB Capital, a subsidiary of Taiwan’s Cathay Financial Holding (stock code: 2883.TT), and Kunshan Guoke Innovation. The fund aims to promote the development of Taiwanese-funded enterprises in mainland China through an empowering investment strategy, fostering cross-strait technological exchanges, and building supply chain and market cooperation. It focuses on investment themes such as the technological advantages of Taiwanese businesses, manufacturing upgrades, and strategic emerging industries. With over 65 years of experience in industrial investment and private equity financing, CDIB Capital has played a significant role in Taiwan’s industrial upgrading. Currently, it manages 16 funds with diverse themes for domestic and overseas investment layouts, with total assets under management exceeding RMB 15 billion.